Breast Cancer Case Study

A pharmaceutical company had a new potential treatment undergoing clinical trials at eight sites within the United States and Canada.   At the time this trial took place, there were several other competing studies and, for this reason, the sponsor struggled to keep sites engaged and motivated to meet enrollment expectations.

VIEW OUR BREAST CANCER CASE STUDY

 


 

Patient Travel and Reimbursements for AL Amyloidosis Study

This three-year rare disease study was being conducted at 75 study sites throughout the United States, Canada, Europe, and Australia. The study required a 13-month commitment from patients, and had a rigorous visit calendar for the first three months of treatment, thus the sponsor was seeking assistance with patient travel and coordination.

VIEW OUR PATIENT TRAVEL CASE STUDY

 


 

Awareness Campaign for Rare Cancer Studies

Two studies testing the same study drug were seeking to recruit patients with rare cancer indications, both with very limited patient populations. Richter’s syndrome is a rare transformation that occurs in about 5-10% of patients with Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma accounts for about 30% of newly diagnosed cases of Non-Hodgkin Lymphoma in the US.

VIEW OUR RARE CANCER CASE STUDY

 


 

Awareness Campaign for Recurrent Anaplastic Astrocytoma

A clinical trial was recruiting patients with recurrent Anaplastic Astrocytoma (AA), a grade 3 glioma. The study was being conducted across the US as well as in a number of European countries. AA affects about 5-8 per 100,000 people, and in order to qualify these patients must be experiencing their first recurrence or progression after surgical resection or chemotherapy treatment.

VIEW OUR ANAPLASTIC ASTROCYTOMA  CASE STUDY